Genetically-engineered mycobacterium strain and a use thereof in the preparation of steroidal compounds

Patent metadata

Field	Value
Publication number	US-10774355-B2
Application number	US-201616310741-A
Country	US
Kind code	B2
Filing date	Jun 16, 2016
Priority date	Jun 16, 2016
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

The present invention relates to a genetically-engineered Mycobacterium strain and a use thereof in the preparation of steroidal compounds. The genetically-engineered Mycobacterium strain is a Mycobacteria which lacks of acyl-CoA dehydrogenase genes fadE31, fadE32 and fadE33, wherein acyl-CoA dehydrogenase genes fadE31, fadE32 and fadE33 respectively encode proteins as follows: having amino acid sequences according to SEQ ID NOs 4, 6 and 8; derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by preceding protein and having the same function as that of the preceding protein. The present invention constructs a genetically-engineered Mycobacterium strain and applies it in preparing steroidal compounds, thereby enriching the types of valuable intermediates, improving the production efficiency and product quality of steroid drugs, reducing energy consumption in the steroid drugs production, simplifying production steps, and reducing production costs.

First claim

What is claimed is:

1. A genetically-engineered Mycobacterium strain, characterized in that the genetically-engineered Mycobacterium strain is a Mycobacteria which lacks of acyl-CoA dehydrogenase genes fadE31, fadE32 and fadE33;
wherein the acyl-CoA dehydrogenase gene fadE31 encodes a protein (i) or (ii) as follows:
(i) having the amino acid sequence according to SEQ ID NO 4;
(ii) derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by (i) and having the same function as that of the protein of (i);
wherein the acyl-CoA dehydrogenase gene fadE32 encodes a protein (iii) or (iv) as follows:
(iii) having the amino acid sequence according to SEQ ID NO 6;
(iv) derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by (iii) and having the same function as that of the protein of (iii); and
wherein the acyl-CoA dehydrogenase gene fadE33 encodes a protein (v) or (vi) as follows:
(v) having the amino acid sequence according to SEQ ID NO 8;
(vi) derived by substituting, deleting or inserting one or more amino acids in the amino acid sequence defined by (v) and having the same function as that of the protein of (v),

wherein said proteins (ii), (iv) and (vi) have at least 75% sequence identity to SEQ ID NOs 4, 6, and 8, respectively.

2. The genetically-engineered Mycobacterium strain according to claim 1 , characterized in that the acyl-CoA dehydrogenase gene fadE31 has the following sequence (1) or (2):
(1) having a nucleotide sequence shown at positions 889-2037 of the sequence according to SEQ ID NO 3;
(2) having a nucleotide sequence that has at least 70% identity to the nucleotide sequence of (1);
wherein the acyl-CoA dehydrogenase gene fadE32 has the following sequence (3) or (4):
(3) having a nucleotide sequence shown at positions 889-1845 of the sequence according to SEQ ID NO 5;
(4) having a nucleotide sequence that has at least 70% identity to the nucleotide sequence of (3);
wherein the acyl-CoA dehydrogenase gene fadE33 has the following sequence (5) or (6):
(5) having a nucleotide sequence shown at positions 886-1821 of the sequence according to SEQ ID NO 7; and
(6) having a nucleotide sequence that has at least 70% identity to the nucleotide sequence of (5).

3. The genetically-engineered Mycobacterium strain according to claim 1 , characterized in that the Mycobacterium species is a fast growing type of Mycobacterium , and the fast growing type of Mycobacterium is selected from a group consisting of: Mycobacterium sp. NRRL B-3683, Mycobacterium sp. NRRLB-3805, Mycobacterium smegmatism, Mycobacterium fortuitum, Mycobacterium gilvum, Mycobacterium neoaurum, Mycobacterium Phlei, Mycobacterium avium , or Mycobacterium vanbaalenii.

4. A method of preparing steroidal compounds comprising: inoculating the genetically-engineered Mycobacterium strain of claim 1 into a culture medium, and adding sterol as a substrate.

5. The method according to claim 4 , characterized in that the steroidal compound is sitolactone.

Assignees

• Univ East China Science & Tech

Inventors

• Wang Fengqing
• Xu Liqin
• Liu Yongjun
• Liu Haohao
• Xiong Liangbin
• Wei Dongzhi

Classifications

• C12R2001/33

  Mycobacterium fortuitum · CPC title

• C12R2001/325

  Mycobacterium avium · CPC title

• C12R2001/34

  Mycobacterium smegmatis · CPC title

• C12P33/02 Primary

  Dehydrogenating; Dehydroxylating · CPC title

• C12R2001/32

  Mycobacterium · CPC title